Marco is a biochemist with expertise in chemical biology and action of drug molecules. While deeply immersed in several experiments during his Marie Curie Fellowship at the University of Cambridge, he realized the great potential of using novel machine learning approaches in drug combinations. This experience led to the development of a companion diagnostic kit and the foundation of biotx.ai.
AI in drug discovery
Starting with millions of drug candidates and narrowing down to one successful candidate, drug development is costly and time-intensive. Entire projects fail because a) the addressed drug target is not central to the disease mechanism and b) the wrong patients were selected in clinical trials. AI analysis of existing clinical data allows for decreasing time, cost and improving success rates demonstrated in three showcases.
- 11:45 am- 1:15 pm: REGIONAL SESSION I: BIOTECH & PHARMA
Location: Stage 2